Early efficacy of liposomal amphotericin B in the treatment of visceral leishmaniasis

被引:10
|
作者
Castagnola, E
Davidson, RN
Fiore, P
Tasso, L
Rossi, G
Mangraviti, S
DiMartino, L
Scotti, S
Cascio, A
Pempinello, R
Gradoni, L
Giacchino, R
机构
[1] G GASLINI CHILDRENS HOSP,DEPT DIETET,I-16147 GENOA,ITALY
[2] G GASLINI CHILDRENS HOSP,LAB CLIN ANAL 1,I-16147 GENOA,ITALY
[3] NORTHWICK PK HOSP & CLIN RES CTR,LISTER INST INFECT & TROP DIS,LONDON,ENGLAND
[4] OSPED PAUSILLIPON,DEPT PAEDIAT 1,NAPLES,ITALY
[5] UNIV PALERMO,OSPED BAMBINI,DEPT INFECT DIS,PALERMO,ITALY
[6] PRESIDIO OSPED D COTUGNO,UNITA SANIT LOCALE 41,NAPLES,ITALY
[7] IST SUPER SANITA,PARASITOL LAB,I-00161 ROME,ITALY
关键词
leishmaniasis; Leishmania infantum; chemotherapy; liposomal amphotericin B; PINI score;
D O I
10.1016/S0035-9203(96)90270-9
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The rapidity and efficacy of a short course of liposomal amphotericin B was evaluated in 29 children affected by visceral leishmaniasis (Leishmania infantum). Their overall health status was assessed using the prognostic inflammatory and nutritional index (Pwr), and their haematological status by the reticulocyte count and haemoglobin blood levels. All these quantities were measured on day 0, and 3 and 10 d after starting therapy. A significant decrease of inflammatory signs, associated with an improved reticulocyte count, was recorded after 3 d of therapy. A significant increase of haemoglobin levels was also observed 10 d after the start of treatment. The early reduction of inflammatory signs and the improvement of bone marrow function in most patients confirmed the validity of amphotericin B therapy. The PINI score is helpful in assessing the severity of visceral leishmaniasis and the follow-up of its treatment.
引用
收藏
页码:317 / 318
页数:2
相关论文
共 50 条
  • [21] EFFICACY OF LIPOSOMAL AMPHOTERICIN-B IN THE TREATMENT OF VISCERAL LEISHMANIASIS IN PATIENTS COINFECTED WITH THE HUMAN-IMMUNODEFICIENCY-VIRUS
    TORRECISNEROS, J
    VILLANUEVA, JL
    CLINICAL INFECTIOUS DISEASES, 1995, 20 (01) : 191 - 191
  • [22] Single-dose liposomal amphotericin B for visceral leishmaniasis
    Kshirsagar, Nilima A.
    LANCET GLOBAL HEALTH, 2014, 2 (04): : E203 - E203
  • [23] Treatment of Disseminated Leishmaniasis With Liposomal Amphotericin B
    Machado, Paulo R. L.
    Rosa, Maria Elisa A.
    Guimaraes, Luis H.
    Prates, Fernanda V. O.
    Queiroz, Adriano
    Schriefer, Albert
    Carvalho, Edgar M.
    CLINICAL INFECTIOUS DISEASES, 2015, 61 (06) : 945 - 949
  • [24] Liposomal amphotericin B as a treatment for human leishmaniasis
    Balasegaram, Manica
    Ritmeijer, Koert
    Lima, Maria Angeles
    Burza, Sakib
    Genovese, Gemma Ortiz
    Milani, Barbara
    Gaspani, Sara
    Potet, Julien
    Chappuis, Francois
    EXPERT OPINION ON EMERGING DRUGS, 2012, 17 (04) : 493 - 510
  • [25] Treatment of cutaneous leishmaniasis with liposomal amphotericin B
    del Rosal Rabes, T.
    Baquero-Artigao, F.
    Gomez Fernandez, C.
    Garcia Miguel, M. J.
    de Lucas Laguna, R.
    ANALES DE PEDIATRIA, 2010, 73 (02): : 101 - 102
  • [26] Visceral leishmaniasis in renal transplant recipients: Successful treatment with liposomal amphotericin B (AmBisome)
    Boletis, JN
    Pefanis, A
    Stathakis, C
    Helioti, H
    Kostakis, A
    Giamarellou, H
    CLINICAL INFECTIOUS DISEASES, 1999, 28 (06) : 1308 - 1309
  • [27] A comparison of liposomal amphotericin B with sodium stibogluconate for the treatment of visceral leishmaniasis in pregnancy in Sudan
    Mueller, Marius
    Balasegaram, Manica
    Koummuki, Youssif
    Ritmeijer, Koert
    Santana, Muriel Ramirez
    Davidson, Robert
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 58 (04) : 811 - 815
  • [28] Treatment of resistant visceral leishmaniasis with interferon gamma in combination with liposomal amphotericin B and allopurinol
    Khodabandeh, Mahmoud
    Rostami, Ali
    Borhani, Katayoun
    Gamble, H. Ray
    Mohammadi, Mohsen
    PARASITOLOGY INTERNATIONAL, 2019, 72
  • [29] Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients
    Molina, I.
    Falco, V.
    Crespo, M.
    Riera, C.
    Ribera, E.
    Curran, A.
    Carrio, J.
    Diaz, M.
    del Saz, S. Villar
    Fisa, R.
    Lopez-Chejade, P.
    Ocana, I.
    Pahissa, A.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2007, 60 (04) : 837 - 842
  • [30] EFFICACY OF INTERMITTENT LIPOSOMAL AMPHOTERICIN-B IN THE TREATMENT OF VISCERAL LEISHMANIASIS IN PATIENTS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS
    LAGUNA, F
    TORRECISNEROS, J
    MORENO, V
    VILLANUEVA, JL
    VALENCIA, E
    CLINICAL INFECTIOUS DISEASES, 1995, 21 (03) : 711 - 712